The shingles vaccine can help you avoid an outbreak of shingles, but research says it may also be able to protect you against ...

D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

After paying almost $200 to get a shingles vaccine they later learned is publicly funded, a Tillsonburg, Ont., couple says ...

Shingrix, the new shingles vaccine, is over 90 percent effective in preventing the painful viral infection Julie Mazziotta is the Senior Sports Editor at PEOPLE, covering everything from the NFL ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Shingrix's efficacy rate is more than 90%, according to GSK. Experts recommend anyone who wants Shingrix to get on the waitlist at a pharmacy, clinic or doctor's office.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Shingrix’s strong showing was mainly the result of a large order from a U.S. retail pharmacy chain, GSK chief commercial officer Luke Miels told investors during a separate call. After the ...